Increasing Global Prevalence Of Blood Related Disorders To Accelerate The Global Drugs And Diagnostics Market For Hematological Disorder

According to a recently published report, the global Hematological Disorder Drugs And Diagnostics Market for hematological disorder is expected to grow at the CAGR 5.6% during 2015-2022. The segmentation of global hematological disorder drugs and diagnostics market is based on product, end-users and geography. The report on global hematological disorder drugs and diagnostics market forecast 2015-2022 (product, end-users and geography) provides detailed overview and predictive analysis of the market.

Full report available global hematological disorder drugs and diagnostics market forecast 2015-2022 (product, end-users and geography) report at http://www.briskinsights.com/report/hematological-disorder-drugs-and-diagnostics-market

The growth and demand of the global hematological disorder drugs and diagnostics market is very high in developed and developing countries. In recent time, major drivers that accelerate the global hematological disorder drug and diagnostics market are increasing. The frequent occurrence of blood related disorders, growing acceptance of automated hematology devices, and increasing expenditure in R&D in the pharmaceutical sector are some of the major key drivers of the market. According to the data collected by Lymphoma and Leukemia Society (LLS), around 10% of US population was diagnosed with blood related disorders like myeloma, leukemia and lymphoma. Moreover, as per the data stated by the National Hemophilia Foundation, there are around 400,000 cases of hemophilia globally. It has been estimated that the geriatric population aged over 65 will cross over the 80 million mark by the year 2050, which will be a major driver for this market in near future. Development of Point of Care (POC) diagnostics, cohesive use of cytometry techniques and analyzers etc. are the major opportunities in global hematological disorders drugs and diagnostic market. POC diagnostics remains major field of interest among laboratories and a significant growth area for this market. POC techniques can be used in the absence of specialized personnel, in extreme field conditions or even at the bedside with no or limited infrastructure; and also, without specialized maintenance services. Though POC techniques is not a solution for all diagnostic needs, it is still a major opportunity in this market. However, involvement of government and stringent regulations; lesser adoption in developing economies; and, high cost of hematology diagnostics devices are major restraints hampering the potential of global hematological disorders drugs and diagnostics market.

Scope of the report

1. Global Hematological Disorder Drugs and Diagnostics Market by Product 2012- 2022 ($ billion)
1.1. Analyzers
1.2. Reagents

2. Global Hematological Disorder Drugs and Diagnostics Market by End-users 2012- 2022 ($ billion)
2.1. Academic and research institutes
2.2. Hospitals
2.3. Clinical Laboratories

3. Global Hematological Disorder Drugs and Diagnostics Market Regional Outlook 2012-2022 ($ billion)
3.1. North America
3.2. Europe
3.3. Asia Pacific
3.4. Middle East & Africa
3.5. Central & South America

4. Company profiles
4.1. Abbot Laboratories
4.2. Amgen
4.3. Beckman Coulter
4.4. Biogen Idec
4.5. Biorad Laboratories
4.6. Bristol-Myers Squibb
4.7. Eli Lilly And Company
4.8. Hemocue Ab
4.9. Horbia
4.10. Mindray Medical International
4.11. Nihon Kohden
4.12. Pfizer
4.13. Roche Diagnostics A/S
4.14. Siemens Ag
4.15. Sysmex